Research Article
Rapid-Onset Obesity with Hypoventilation, Hypothalamic, Autonomic Dysregulation, and Neuroendocrine Tumors (ROHHADNET) Syndrome: A Systematic Review
Table 5
Treatment of case-reported patients with ROHHADNET syndrome (IPD).
| | Treatment | Total number of patients (n = 48) | | Number of patients () |
| | Respiratory support | 21 (43.8) | | Mechanical ventilation | 20 (41.7%) | | BIPAP | 7 (14.6%) | | CPAP | 1 (2.1%) | | Noninvasive mask | 1 (2.1%) | | Tracheostomy | 6 (12.5%) | | Steroids | 7 (14.6) | | Methylprednisolone | 2 (4.2%) | | Steroid pulse therapy | 2 (4.2%) | | Prednisolone | 2 (2.1%) | | Dexamethasone | 1 (2.1%) | | Fluid resuscitation | 4 (8.3) | | Intravenous immunoglobulins | 7 (14.6) | | Immunosuppressive agents | 7 (14.6) | | Rituximab | 5 (10.4%) | | Cyclophosphamide | 6 (12.5%) | | Other agents | | | Antipsychotics | 3 (6.3%) | | Desmopressin acetate | 2 (4.2%) | | GH replacement | 2 (4.2%) | | Anti-epileptics | 2 (4.2%) | | Levothyroxine | 4 (8.3%) | | Caffeine | 1 (2.1%) | | Hypertensive medication | 1 (2.1%) | | Procedure | 2 (4.2) | | Brain hypothermia | 1 (2.1%) | | Tonsillectomy | 1 (2.1%) |
|
|
BIPAP: bilevel positive airway pressure; CPAP: Continuous Positive Airway Pressure; GH: growth hormone.
|
